The Journal is included in Russian and International Library and Abstract Databases
Russain Science Index (Russia)
DOI Registration Agency (USA)

Treatment options for overactive bladder and urinary incontinence in patients with comorbid conditions


Professor S. Kotov, MD; D. Bogdanov N.I. Pirogov Russian National Research Medical University,

Overactive bladder (OAB) and urinary incontinence (UI) have high prevalence in both genders after the age of 40 years. Urgency is the leading OAB symptom negatively impacted on patient quality of life. Antimuscarinic therapy is the primary of OAB and UI treatment. Solifenacin due to high-selectivity relieves OAB symptoms while good tolerability including patients with cardio-vascular comorbidity and seniors and improves quality of life. Management of women in postmenopause and men with benign prostatic hyperplasia needs complex treatment approach. Generics improves therapy affordable and treatment adherence.

overactive bladder
urinary incontinence

  1. Kasjan G.R. i dr. Sindrom giperaktivnogo mochevogo puzyrja v klinicheskoj praktike vracha-urologa. Metodicheskie rekomendatsii. M.: ABV-press, 2019; 36 s. [Kasyan G.R. et al. Sindrom giperaktivnogo mochevogo puzyrya v klinicheskoi praktike vracha-urologa. Metodicheskie rekomendatsii. M.: ABV-press, 2019; 36 s. (in Russ.)].
  2. Mostafaei H., Sadeghi-Bazargani H., Hajebrahimi S. et al. Prevalence of female urinary incontinence in the developing world: A systematic review and meta-analysis-A Report from the Developing World Committee of the International Continence Society and Iranian Research Center for Evidence Based Medicine. Neurourol Urodyn. 2020; 39 (4): 1063–86. DOI: 10.1002/nau.24342
  3. Milsom I., Abrams P., Cardozo L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87 (9): 760–6. DOI: 10.1046/j.1464-410x.2001.02228.x. Erratum in: BJU Int. 2001; 88 (7): 807.
  4. Haab F., Cardozo L., Chapple C. et al. Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005; 47 (3): 376–84. DOI: 10.1016/j.eururo.2004.11.004
  5. Lee S.H., Kang J.S., Kim J.W. et al. Incontinence pad usage in medical welfare facilities in Korea. Int Neurourol J. 2013; 17 (4): 186–90. DOI: 10.5213/inj.2013.17.4.186
  6. Chapple C.R., Martinez-Garcia R., Selvaggi L. et al. STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005; 48 (3): 464–70. DOI: 10.1016/j.eururo.2005.05.015
  7. Pelman R.S., Capo J.P., Forero-Schwanhaeuser S. Solifenacin at 3 Years: A Review of Efficacy and Safety. Postgraduate Medicine. 2008; 120 (2): 85–91. DOI: 10.3810/pgm.2008.07.1795
  8. Luo D., Liu L., Han P. et al. Solifenacin for overactive bladder: a systematic review and meta-analysis. Int Urogynecol J. 2012; 23 (8): 983–91. DOI: 10.1007/s00192-011-1641-7
  9. Nazir J., Kelleher C., Aballéa S. et al. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis. Neurourol Urodyn. 2017; 37 (3): 986–96. DOI: 10.1002/nau.23413
  10. Kelleher C., Hakimi Z., Zur R. et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol. 2018; 74 (3): 324–33. DOI: 10.1016/j.eururo.2018.03.020
  11. Jiang F., Zhu L., Xu T. et al. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women – a multicenter, randomized, open-label, controlled comparison study. Menopause. 2016; 23 (4): 451–7. DOI: 10.1097/GME.0000000000000574
  12. Hampel C., Betz D., Burger M. et al. Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects. Urol Int. 2017; 98 (3): 350–7. DOI: 10.1159/000455257
  13. Gong M., Dong W., Huang G. et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015; 31 (9): 1781–92. DOI: 10.1185/03007995.2015.1074067
  14. Cetinel B., Onal B., Gultekin M.H. et al. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial. Int Urol Nephrol. 2019; 51 (3): 417–24. DOI: 10.1007/s11255-019-02090-9
  15. Arana A., Margulis A. V., McQuay L.J. et al. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study. Pharmacotherapy. 2018; 38 (6): 628–37. DOI: 10.1002/phar.2121